Drug delivery integrated circuit (IC) and system

Patent metadata

Field	Value
Publication number	US-11285307-B2
Application number	US-201715999657-A
Country	US
Kind code	B2
Filing date	Feb 17, 2017
Priority date	Feb 19, 2016
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

Wireless and non-wireless drug delivery integrated circuits, systems, and methods of delivering therapeutic pharmaceutical compounds are provided. The system can include a control module, a wireless drug delivery integrated circuit, a first electrode and a second electrode that are both attached to the wireless drug delivery integrated circuit, an electroactive polymer, and a pharmaceutical compound. The electroactive polymer and the pharmaceutical compound can be formed as films on one of the electrodes and, when placed in a solution, a voltage potential can be applied across the electrodes causing the pharmaceutical compound to be released into the solution.

First claim

What is claimed is:

1. A drug delivery system, comprising:
a control module;
a wireless drug delivery integrated circuit;
a first electrode and a second electrode, wherein the first electrode and the second electrode are both attached to the wireless drug delivery integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound, wherein the first pharmaceutical compound is released into a first solution in a chamber in response to a first voltage difference applied between the first electrode and the second electrode.

2. The drug delivery system according to claim 1 , wherein the first electroactive polymer and the first pharmaceutical compound are layered as films on the first electrode.

3. The drug delivery system according to claim 1 , wherein the wireless drug delivery integrated circuit includes multiple antennas configured to supply energy to the wireless drug delivery integrated circuit.

4. The drug delivery system according to claim 1 , wherein the first electrode comprises a bioinert glassy carbon, and wherein the second electrode comprises platinum.

5. The drug delivery system according to claim 1 ,
wherein the control module includes a graphical user interface that displays a temperature received from the wireless drug delivery integrated circuit and is configured to control the wireless drug delivery integrated circuit, and
wherein the graphical user interface includes options of voltage applied, voltage duration, initiation of the voltage applied, and stopping the voltage applied.

6. The drug delivery system according to claim 1 , wherein the first electrode and the second electrode are contained in a first chamber with the first pharmaceutical compound, and wherein the drug delivery system further comprises a third electrode and a fourth electrode in a second chamber with a second pharmaceutical compound.

7. The drug delivery system according to claim 6 , further comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and
a second inlet, a second outlet, and a second micropump in the second chamber.

8. The drug delivery system according to claim 6 , further comprising:
a first inlet in the first chamber;
a second inlet in the second chamber;
a flow control connected to the first inlet and the second inlet;
a micropump connected to the flow control; and
an outlet connected to the micropump.

9. A drug delivery method, comprising:
providing a wireless drug delivery integrated circuit;
providing a control module suitable for controlling the wireless drug delivery integrated circuit;
providing a first electrode and a second electrode, which are both attached to the wireless drug delivery integrated circuit;
providing a first electroactive polymer;
providing a first pharmaceutical compound;
releasing the first pharmaceutical compound into a first solution in a chamber by generating a first voltage difference between the first electrode and the second electrode.

10. The method according to claim 9 , further comprising:
providing a third electrode and a fourth electrode and releasing a second pharmaceutical compound.

11. The method according to claim 9 , further comprising:
providing a first chamber that contains the first solution, the first electrode, and the second electrode;
providing a first inlet, a first micropump, and a first outlet; and
controlling a release of the first pharmaceutical compound out of the first chamber using the first inlet, the first micropump and the first outlet.

12. The method according to claim 9 , wherein the first electroactive polymer and the first pharmaceutical compound are layered in films on the first electrode.

13. The method according to claim 9 , wherein the first electroactive polymer comprises oligoanilines linked to polycaprolactone (PCL) via ester bonds.

14. A drug delivery system, comprising:
a drug delivery integrated circuit;
a first electrode and a second electrode, which are both attached to the drug delivery
integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound, wherein the first electroactive polymer and the first pharmaceutical compound are layered as films on the first electrode;
wherein a voltage is applied across the first electrode and the second electrode,
wherein a voltage threshold is triggered by a measurement threshold, and
wherein the measurement threshold is at least one of a timing sequence and a solution concentration, where the solution concentration is at least one of a sugar concentration, a salt concentration, and a hormone concentration.

15. The drug delivery system according to claim 14 , wherein the first electrode comprises a bioinert glassy carbon, and
wherein the second electrode comprises at least one of steel, platinum, iridium oxide, gold, magnesium, tungsten, silicon, and platinum-iridium.

16. The drug delivery system according to claim 14 , wherein the first electrode and the second electrode are contained in a first chamber with the first pharmaceutical compound, and
wherein the drug delivery system further comprises a third electrode and a fourth electrode in a second chamber with a second pharmaceutical compound.

17. The drug delivery system according to claim 16 , further comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and
a second inlet, a second outlet, and a second micropump in the second chamber.

18. The drug delivery system according to claim 16 , further comprising:
a first inlet in the first chamber;
a second inlet in the second chamber;
a flow control connected to the first inlet and the second inlet;
a micropump connected to the flow control;
and an outlet connected to the micropump.

Assignees

• Univ Florida

Inventors

• Hur Byul
• Hardy John
• Eisenstadt William R
• Schmidt Christine E

Classifications

• A61B5/746

  Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms · CPC title

• A61M2205/502

  User interfaces, e.g. screens or keyboards · CPC title

• A61M2205/0283

  Electro-active polymers [EAP] · CPC title

• A61M37/00 Primary

  Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04) · CPC title

• A61M31/002

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title